184 related articles for article (PubMed ID: 37347180)
1. Evaluation of Ortho VITROS and Roche Elecsys S and NC Immunoassays for SARS-CoV-2 Serosurveillance Applications.
Sulaeman H; Grebe E; Dave H; McCann L; Di Germanio C; Sanghavi A; Sclar V; Bougie DW; Chatelain G; Biggerstaff BJ; Jones JM; Thornburg NJ; Kleinman S; Stone M; Busch MP
Microbiol Spectr; 2023 Aug; 11(4):e0323422. PubMed ID: 37347180
[TBL] [Abstract][Full Text] [Related]
2. Concordance of SARS-CoV-2 Antibody Results during a Period of Low Prevalence.
Miller CN; Althoff KN; Schlueter DJ; Anton-Culver H; Chen Q; Garbett S; Ratsimbazafy F; Thomsen I; Karlson EW; Cicek M; Pinto LA; Malin BA; Ohno-Machado L; Williams C; Goldstein D; Kouame A; Ramirez A; Gebo KA; Schully SD;
mSphere; 2022 Oct; 7(5):e0025722. PubMed ID: 36173112
[TBL] [Abstract][Full Text] [Related]
3. SARS-CoV-2 Antibody Testing in Health Care Workers: A Comparison of the Clinical Performance of Three Commercially Available Antibody Assays.
Allen N; Brady M; Carrion Martin AI; Domegan L; Walsh C; Houlihan E; Kerr C; Doherty L; King J; Doheny M; Griffin D; Molloy M; Dunne J; Crowley V; Holmes P; Keogh E; Naughton S; Kelly M; O'Rourke F; Lynagh Y; Crowley B; de Gascun C; Holder P; Bergin C; Fleming C; Ni Riain U; Conlon N;
Microbiol Spectr; 2021 Oct; 9(2):e0039121. PubMed ID: 34585976
[TBL] [Abstract][Full Text] [Related]
4. Point of care detection of SARS-CoV-2 antibodies and neutralisation capacity-lateral flow immunoassay evaluation compared to commercial assay to inform potential role in therapeutic and surveillance practices.
McGrath J; O'Doherty L; Conlon N; Dunne J; Brady G; Ibrahim A; McCormack W; Walsh C; Domegan L; Walsh S; Kenny C; Allen N; Fleming C; Bergin C
Front Public Health; 2023; 11():1245464. PubMed ID: 37841735
[TBL] [Abstract][Full Text] [Related]
5. Nucleocapsid and Spike Protein-Based Anti-SARS-CoV-2 Assay Performance in the Minority and Rural Coronavirus Insights Study: Characteristics of Socioeconomically Disadvantaged Populations with Health Disparities.
Christenson RH; Hansel S; II'yasova D; Meyer WA; Puckrein G; Lee L; Landry LG; Akinboboye O
J Appl Lab Med; 2024 May; 9(3):493-501. PubMed ID: 38384143
[TBL] [Abstract][Full Text] [Related]
6. The influence of time on the sensitivity of SARS-CoV-2 serological testing.
Torres Ortiz A; Fenn Torrente F; Twigg A; Hatcher J; Saso A; Lam T; Johnson M; Wagstaffe H; Dhillon R; Mai AL; Goldblatt D; Still R; Buckland M; Gilmour K; Grandjean L
Sci Rep; 2022 Jun; 12(1):10517. PubMed ID: 35732870
[TBL] [Abstract][Full Text] [Related]
7. SARS-CoV-2 serology: Validation of high-throughput chemiluminescent immunoassay (CLIA) platforms and a field study in British Columbia.
Sekirov I; Barakauskas VE; Simons J; Cook D; Bates B; Burns L; Masud S; Charles M; McLennan M; Mak A; Chahil N; Vijh R; Hayden A; Goldfarb D; Levett PN; Krajden M; Morshed M
J Clin Virol; 2021 Sep; 142():104914. PubMed ID: 34304088
[TBL] [Abstract][Full Text] [Related]
8. A Dried Blood Spot protocol for high-throughput quantitative analysis of SARS-CoV-2 RBD serology based on the Roche Elecsys system.
Castelletti N; Paunovic I; Rubio-Acero R; Beyerl J; Plank M; Reinkemeyer C; Kroidl I; Noreña I; Winter S; Olbrich L; Janke C; Hoelscher M; Wieser A;
Microbiol Spectr; 2024 Apr; 12(4):e0288523. PubMed ID: 38426747
[TBL] [Abstract][Full Text] [Related]
9. Persistence of anti-SARS-CoV-2 antibodies: immunoassay heterogeneity and implications for serosurveillance.
Perez-Saez J; Zaballa ME; Yerly S; Andrey DO; Meyer B; Eckerle I; Balavoine JF; Chappuis F; Pittet D; Trono D; Kherad O; Vuilleumier N; Kaiser L; Guessous I; Stringhini S; Azman AS;
Clin Microbiol Infect; 2021 Nov; 27(11):1695.e7-1695.e12. PubMed ID: 34245905
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the Roche SARS-CoV-2 Rapid Antibody Test in Samples from Vaccinated Individuals.
Hayer J; Urlaub E
Microbiol Spectr; 2022 Jun; 10(3):e0270921. PubMed ID: 35575594
[TBL] [Abstract][Full Text] [Related]
11. Analytical and Clinical Analysis of Two Automated Anti-SARS-CoV-2 Immunoassays in Pre-Pandemic and Pandemic Patient Populations.
Yang J; Pederson EC; Hamilton C; Neibauer T; Robyak K; McGhee P; Speicher T; Zhu Y
J Appl Lab Med; 2021 Mar; 6(2):441-450. PubMed ID: 33152084
[TBL] [Abstract][Full Text] [Related]
12. A comparison of SARS-CoV-2 nucleocapsid and spike antibody detection using three commercially available automated immunoassays.
Poore B; Nerenz RD; Brodis D; Brown CI; Cervinski MA; Hubbard JA
Clin Biochem; 2021 Sep; 95():77-80. PubMed ID: 34118242
[TBL] [Abstract][Full Text] [Related]
13. Validation of Commercial SARS-CoV-2 Immunoassays in a Nigerian Population.
Ige F; Hamada Y; Steinhardt L; Iriemenam NC; Uwandu M; Greby SM; Aniedobe M; Salako BL; Rangaka MX; Abubakar I; Audu R
Microbiol Spectr; 2021 Oct; 9(2):e0068021. PubMed ID: 34612691
[TBL] [Abstract][Full Text] [Related]
14. Head-to-head comparison of two rapid high-throughput automated electrochemiluminescence immunoassays targeting total antibodies to the SARS-CoV-2 nucleoprotein and spike protein receptor binding domain.
Poljak M; Oštrbenk Valenčak A; Štamol T; Seme K
J Clin Virol; 2021 Apr; 137():104784. PubMed ID: 33711693
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Two Automated Immunoassays for the Detection of SARS-CoV-2 Nucleocapsid Antibodies.
Hubbard JA; Geno KA; Khan J; Szczepiorkowski ZM; de Gijsel D; Ovalle AA; AlSalman AS; Gallagher TL; Johnston AA; Tibbetts AR; Vital SE; Cervinski MA; Nerenz RD
J Appl Lab Med; 2021 Mar; 6(2):429-440. PubMed ID: 32976593
[TBL] [Abstract][Full Text] [Related]
16. Assessment of serological assays for identifying high titer convalescent plasma.
Farnsworth CW; Case JB; Hock K; Chen RE; O'Halloran JA; Presti R; Goss CW; Rauseo AM; Ellebedy A; Theel ES; Diamond MS; Henderson JP
Transfusion; 2021 Sep; 61(9):2658-2667. PubMed ID: 34216156
[TBL] [Abstract][Full Text] [Related]
17. Validation of N Protein Antibodies to Diagnose Previous SARS-CoV-2 Infection in a Large Cohort of Healthcare Workers: Use of Roche Elecsys
Delgado JF; Vidal M; Julià G; Navarro G; Serrano RM; van den Eynde E; Navarro M; Calvet J; Gratacós J; Espasa M; Peña P
Viruses; 2023 Apr; 15(4):. PubMed ID: 37112910
[TBL] [Abstract][Full Text] [Related]
18. SARS-CoV-2 anti-nucleocapsid assay performance in healthcare workers at baseline and 6 months.
Kerr C; Allen N; Hughes G; Kelly M; O'Rourke F; Lynagh Y; Dunne J; Crowley B; Conlon N; Bergin C
Ir J Med Sci; 2022 Jun; 191(3):1089-1092. PubMed ID: 34235708
[TBL] [Abstract][Full Text] [Related]
19. Comparative study of six SARS-CoV-2 serology assays: Diagnostic performance and antibody dynamics in a cohort of hospitalized patients for moderate to critical COVID-19.
Chamkhi S; Dhaouadi T; Sfar I; Mokni S; Jebri A; Mansouri D; Ghedira S; Ben Jemia E; Ben Boujemaa S; Houissa M; Aouina H; Ben Abdallah T; Gorgi Y
Int J Immunopathol Pharmacol; 2022; 36():20587384211073232. PubMed ID: 35113728
[TBL] [Abstract][Full Text] [Related]
20. Seroprevalence of anti-SARS-CoV-2 antibodies 6 months into the vaccination campaign in Geneva, Switzerland, 1 June to 7 July 2021.
Stringhini S; Zaballa ME; Pullen N; Perez-Saez J; de Mestral C; Loizeau AJ; Lamour J; Pennacchio F; Wisniak A; Dumont R; Baysson H; Richard V; Lorthe E; Semaani C; Balavoine JF; Pittet D; Vuilleumier N; Chappuis F; Kherad O; Azman AS; Posfay-Barbe K; Kaiser L; Guessous I;
Euro Surveill; 2021 Oct; 26(43):. PubMed ID: 34713799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
